A Wedbush analyst raised its target on a French biopharma’s ulcerative colitis candidate but disputed bullish efficacy claims, flagging Jak competition and a 2027 Crohn’s readout.
On July 6, 2026, David Nierengarten, Ph.D., Martin Fan, Ph.D., and Dennis Pak of Wedbush Securities reiterated a NEUTRAL rating and raised their 12-month price target to US$140.00 (from US$110.00) on Abivax SA (ABVX:NASDAQ), implying roughly 3.2% downside from the July 2, 2026 closing price of US$144.65, because the analysts believe the stock’s rebound to pre-Phase 3 maintenance-data levels already reflects a “perfection” scenario for lead candidate obefazimod while overstating bullish claims about its competitive profile.
Rebound and the Safety Debate
Wedbush attributes much of the share-price recovery to investor relief that malignancies reported at the most efficacious 50 mg dose were “merely” in line with the rates that produced black box warnings for the Jak inhibitor class, including market leader Rinvoq (from AbbVie Inc., NYSE: ABBV).
The analysts argue two ideas can hold simultaneously: obefazimod 50 mg dosing carries malignancy rates equivalent to the black-boxed Jak class, yet, as evidenced by Jak-class sales in IBD, malignancies at that level are no great inhibitor of sales. They view the ultimate label as a discussion for roughly 1.5 years out.
Disputing the ‘Best in Disease’ Thesis
The report pushes back directly on the bull refrain that the Phase 3 results are “best in disease,” stating flatly that this claim “is not true.” While obefazimod showed statistically significant induction in heavily pre-treated patients, Wedbush contends that, absent an active comparator in that post-Jak setting, the achievement is “akin to being the world’s loudest whisper.” The analysts favor comparing patients with inadequate response to a biologic who have not yet received a Jak inhibitor.
In that framing, obefazimod delivered placebo-adjusted clinical remission of 11.4% among ATIR patients excluding Jak inhibitors (ECCO 2026) — about half of Rinvoq’s 22.2% benefit in its most-refractory subgroups (Vermiere et al., 2023, consistent with the FDA label range of 17–28%).
Obefazimod’s overall induction of roughly 16% in the ABTECT studies sits notably below Rinvoq, though maintenance data are more comparable (obefazimod 39–40% versus a 34–42% Rinvoq label range in biologic failures). The conclusion: Obefazimod is not the best for the disease.
Commercial and Competitive Outlook
Because patients who fail induction are unlikely to continue therapy, Wedbush expects obefazimod to treat roughly two-thirds of the patients Rinvoq would treat over one year with similar starting cohorts. The analysts agree that obefazimod could be used in the post-Jak setting, but disagree that it will displace the Jaks and their extensive real-world experience. They flag Rinvoq’s generic entry in April 2037 as nearly as dangerous to obefazimod’s position as its own patent expires in 2039, and model declining obefazimod sales once Rinvoq loses exclusivity.
M&A Prospect?
Wedbush sees a diminishing case for a bid within the next ~12 months.
Valuation and estimates
The revised price target derives from a sum-of-parts DCF of 2027–39E worldwide net income from obefazimod in ulcerative colitis and Crohn’s disease, discounted back at 11%, with full credit given to Crohn’s despite its earlier stage. Wedbush characterizes the US$140 figure as a “perfection” valuation that requires sales to eventually approach IBD market leader Entyvio (from Takeda Pharmaceutical Company Limited, NYSE: TAK; Tokyo: 4502), adding “we are not worried ABVX will reach it.” The changes to the model stem from incorporating recent financing. The firm now models a full-year 2026E GAAP loss of €3.10 per share and a 2027E loss of €3.68 per share, against a market cap near US$10.9 billion, cash of US$7.28 per share, and a 52-week range of US$7.65–US$148.83.
Milestones and risks
Upcoming catalysts include a 4Q26 FDA NDA submission for obefazimod in UC, an IBD combination-therapy candidate selection by year-end 2026, and mid-2027 topline data from the Phase 2 ENHANCE-CD study in Crohn’s disease. Key risks cited are clinical and regulatory failure of obefazimod, an inability to achieve sales estimates, potential safety signals, commercial competition, and drug manufacturing or shipment challenges. Wedbush also notes that an acquisition could yield a price sharply higher than its target.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports’ newsletter. | Subscribe |
Important Disclosures:
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
Disclosures for Wedbush, Abivax SA, July 6, 2026
Valuation Sum-of-parts: a DCF valuation of 2027-39E ww net income derived from obefazimod in UC and CD (discounted back by 11%) Company Description ABVX is a clinical-stage biopharmaceutical company developing treatments for inflammatory and immune-mediated diseases (I&I). Lead program obefazimod is a first-in-class enhancer of a microRNA sequence, miR-124. Wedbush Best Ideas List The Wedbush Equity Research Department is focused on delivering alpha within the Life Sciences and TMT verticals. The Best Ideas List comprises our highest rated equities, chosen by our analysts, and vetted by our Investment Committee. To manage risk and avoid thesis creep, we employ an automatic sale rule should a stock move -25% on a relative basis (versus the average move of the S&P 500 and the Russell 2000). Past performance is not an indicator of future results. Actual performance may differ from the performance information contained herein. The prices and performance information are based on data from statistical services, reports, or other sources which WS believes are reliable, but its accuracy cannot be guaranteed. Results presented in this report neither reflect inclusion of dividends nor deductions for commissions, costs, fees, or expenses. Such commissions, costs, fees, or expenses will reduce the actual returns. The volatility of the S&P 500 and/or any other benchmark index presented is materially different from that of the model portfolio and is used to illustrate the general market condition on the results portrayed. Benchmark Indices are unmanaged and cannot be invested in directly. Risks to the Attainment of Our Price Target and Rating: Risks to the attainment of our price target and rating for ABVX include clinical and regulatory failure of obefazimod in target indications, and an inability to achieve sales estimates. The company’s lead programs may not prove to be efficacious, or safety signals could halt development. Obefazimod could face commercial challenges from current and future therapies, and logistical challenges in drug manufacturing or shipment could arise. An acquisition could also yield a price sharply higher than our target. Analyst Certification We, David Nierengarten, Martin Fan and Dennis Pak, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report. Mentioned Companies Company Rating Price Target Abivax S.A. NEUTRAL €144.65 €140.00 Investment Rating System: OUTPERFORM: Expect the total return of the stock to outperform relative to the median total return of the analyst’s (or the analyst’s team) coverage universe over the next 6-12 months. NEUTRAL: Expect the total return of the stock to perform in-line with the median total return of the analyst’s (or the analyst’s team) coverage universe over the next 6-12 months. UNDERPERFORM: Expect the total return of the stock to underperform relative to the median total return of the analyst’s (or the analyst’s team) coverage universe of the next 6-12 months. The Investment Ratings are based on the expected performance of a stock (based on anticipated total return to price target) relative to the other stocks in the analyst’s coverage universe (or the analyst’s team coverage).* Rating distribution (as of July 6, 2026) Investment Banking Relationships (as of July 6, 2026) OUTPERFORM: 76.10% OUTPERFORM: 13.61% NEUTRAL: 21.91% NEUTRAL: 9.09% UNDERPERFORM: 1.99% UNDERPERFORM: 0.00%
The Distribution of Ratings is required by FINRA rules; however, WS’ stock ratings of Outperform, Neutral, and Underperform most closely conform to Buy, Hold, and Sell, respectively. Please note, however, the definitions are not the same as WS’ stock ratings are on a relative basis. The analysts responsible for preparing research reports do not receive compensation based on specific investment banking activity. The analysts receive compensation that is based upon various factors including WS’ total revenues, a portion of which are generated by WS’ investment banking activities. Company Specific Disclosures This information is subject to change at any time. This research is provided for educational and informational purposes only and is not intended to be relied upon as a forecast, research, or investment advice, and is not a recommendation, offer, or solicitation to buy or sell any securities or to adopt any investment strategy. Investing involves risk, including the risk of loss of principal. Your investments may decline in value due to both real and perceived general market, economic, and industry conditions. Diversification does not ensure profits or protect against loss. This research was prepared without regard to specific investment objectives, strategies, tax status, investment horizon, financial situation or needs of any investor. Wedbush Securities, Inc. (“WSI”) encourages recipients of this report to read all relevant offering documents (e.g., prospectus) pertaining to any investment concerned, including without limitation, information relevant to its investment objectives, risks, and costs before making an investment decision and when deemed necessary, to seek the advice of a legal, tax, and/or accounting professional. Past performance is no guarantee of future results. Reliance upon information in this research is at the sole discretion of the reader. All information in this research is believed to be reliable as of the date on which this research was issued and has been obtained from public sources believed to be reliable. No representation or warranty, either express or implied, is provided in relation to the accuracy or completeness of the information contained herein. The opinions expressed are as of the date written and are subject to change without notice. In addition, this research may contain certain statements deemed to be “forward-looking” statements. All statements, other than historical facts, contained within this document that address activities, events or developments that this research report expects, believes, or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions and analyses made by WSI in light of its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. Such statements are subject to assumptions, risks, uncertainties, many of which are beyond WSI’s control. Please note that any such statements are not guarantees of any future performance and that actual results or developments may differ materially from those projected in the forward-looking statements. Prepared by Wedbush Securities, Inc., a member of FINRA and SIPC. 1. WS makes a market in the securities of Abivax S.A..
Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to [email protected]. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019. OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.
